RECRUITINGINTERVENTIONAL
Control Cohort CTRL COH
About This Trial
Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare disease that could be difficult to diagnose. So it necessary to obtain numerous sample from different disease to develop more specific diagnosis kit It could be possible through the characterisation of new genetic biomarkers.
Who May Be Eligible (Plain English)
Who May Qualify:
- patient with consent
- patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.
Who Should NOT Join This Trial:
- refusal consent
- patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis
- patient under guardianship
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* patient with consent
* patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.
Exclusion Criteria:
* refusal consent
* patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis
* patient under guardianship
Treatments Being Tested
BIOLOGICAL
Collection of biological sample (blood and/or CSF)
Blood sample will be collected one time for each patient: 2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml).
Locations (1)
Hospices Civils de Lyon
Bron, France